EORTC Presentations at ECC2015 in Vienna

The EORTC will have an active presence at this year’s European Cancer Congress, ECC 2015 :

• EORTC Society Session
• Best Abstract – The impact of pathological factors on long-term local control in the EORTC boost no-boost trial
• Late Breaking, Oral, and Poster abstracts
• Plus presentations at Scientific, Patient Advocacy, Cancer Survivorship, Oncopolicy, and Special sessions

EORTC Society Session: Precision Medicine: Are We Stalling?

Time: Monday, 28 September 2015 from 9:15 – 11:15

Location: Hall C1
Chairs: EORTC Roger Stupp and Denis Lacombe

 

 

Vassilis Golfinopoulos, EORTC Medical Director, will investigate “Is there space for research beyond molecular defined subgroups?” Key topics of his talk include the current status of research regarding molecular subgroups, opportunities and pitfalls of integration of molecular subgroups in clinical trials, and potential research areas beyond current trends. EORTC

 

 Jan Bogaerts, EORTC Methodology Director, will look at “Precision medicine: Are randomized trials obsolete?” Key topics covered in his talk will be randomization, trial design, and precision medicine.

 

 
Ultan McDermott, Career Development Fellow Group Leader in the Cancer Genome Project and a practicing medical oncologist at Addenbrooke’s Hospital in Cambridge, will delve into “Bioinformatics – the bottleneck to technology platforms?”

 

Finally, Francesco Pignatti, Head of Oncology, Haematology, Diagnostics – Safety and Efficacy Sector at European Medicines Agency, will talk about “New regulatory pathways for biomarker and cancer drug access”.

 

 

Best Abstract

Abstract ID: 1BA
Session: Presidential Session II
Time:  Sunday, 27 September 2015, 14:45
Location: Hall D1

C. Vrieling, E. van Werkhoven, P. Poortmans, H. Struikmans, C. Weltens, A. Fourquet, J. Jager, D. Schinagl, L. Collette, P. Maingon, H. Bartelink
The impact of pathological factors on long-term local control in the EORTC boost no-boost trial
(N.B.: Patients with stage I and II breast cancer who underwent breast-conserving therapy.)

Oncopolicy Forum: Tackling Rare Cancers Requiring Specialist Care: European Reference Networks

Time: Monday, 28 September 2015, 17:30
Location: Hall A3

Denis Lacombe, EORTC, will present “The research perspective: SPECTArare”. He will address new approaches for clinical and translational research for rare tumors, the optimization new methodologies, regulatory pathways and operations for drug development in rare tumors, and discuss new types of pan-European infrastructure for rare tumors.

Patient Advocacy Session: Inequalities in Genetic and Biomolecular Testing

Time: Saturday, 28 September 2015 at 15:35
Location: Hall A3

Vassilis Golfinopoulos, EORTC Medical Director, will present “How genetics can help your treatment – the EORTC SPECTA program”. His presentation will explain what genetic testing can and cannot currently deliver and the steps required to introduce genetic testing in the clinic.
Present how the EORTC SPECTA program is approaching the collection of molecular evidence and the integration of such evidence in clinical trials.

Scientific Symposium: Making Survivor Care Evidence Based for the Growing Number of Survivors: Patients at the Forefront of Their Own Survivorship Care

Time: Monday, 28 September 2015, 17:20
Location: Stolz 1

Lotte Moser, Radiation Oncologist at the Champalimaud Foundation, will present “Exploiting dormant information on long-term follow-up outcome of EORTC Lymphoma trials: The EORTC survivorship initiative”. She will discuss the importance of long-term follow up Survivorship issues and how to manage large data and obtain long-term information in cancer survivors using the EORTC Lymphoma Group updates as an example.

Special Session: ECCO-AACR-EORTC-ESMO Workshop on Methods in Clinical Cancer Research: How to Design Good Clinical Trials

Time:  Sunday, 27 September 2015, 16:45 18:15
Location: The Study
This session is chaired by J.R. van der Vorst and will include presentations by S. Sleijfer, T. Yap, S. Essiaf, F. Cardoso, and P. Haluska.

Oral Presentations

Abstract ID: 3401
Proffered Paper Session: Sarcoma: Soft Tissue and Bone
Time:  Saturday, 26 September 2015 at 10:45
Location: LEHAR 3

Viktor Grünwald, Saskia Litière, Robin Young, Christina Messiou, Michela Lia, Eva Wardelmann, Winette van der Graaf, Alessandro Gronchi, Ian Judson
Absence of progression, not extent of remission defines prognosis in soft tissue sarcoma – an analysis of the EORTC 62012 study

Abstract ID: 2200
Proffered Paper Session: Gastrointestinal Malignancies – Noncolorectal Cancer
Time: Tuesday, 29 September 2015, 8:30
Location: Hall C2

T. Leong, M. Smithers, M. Michael, V. Gebski, J. Simes, A. Boussioutas, D. Miller, J. Zalcberg, R. O’Connell, C. Swallow, G. Darling, R. Wong, C. Schuhmacher, F. Lordick, K. Haustermans
TOPGEAR: A randomized phase II/III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer.  Interim results from an international, intergroup trial of the AGITG/TROG/NCIC CTG/EORTC

Late Breaking Abstracts

Abstract ID: 13LBA
Proffered Paper Session: Sarcoma: Soft Tissue and Bone
Time: Saturday, 26 September 2015, 12:20
Location: Lehar 3
Rolf Issels

Issels RD, Lindner LH, Ghadjar P, Reichardt P, Hohenberger P, Verweij J, Abdel-Rahman S, Daugaard S, Salat C, Vujaskovic Z, Wessalowski R, Duerr HR, Ploner F, ¹Mella O, Schmidt M, Mansmann U, Jauch KW, Belka C, Hiddemann W, Gronchi A
Improved overall survival by adding regional hyperthermia to neo-adjuvant chemotherapy in patients with localized high-risk soft tissue sarcoma (HR-STS): Long-term outcomes of the EORTC 62961/ESHO randomized phase III study

Poster Presentations

Abstract ID: 3439; P304
Session: Sarcoma: Soft Tissue and Bone
Time:  Saturday, 26 September 2015, 16:45 – 18:45
Location: Hall C

Lindner LH, Litière S, Sleijfer S, Judson I, Italiano A, Kasper B, Gelderblom H, Marreaud S, Wardelmann E, Gronchi A, van der Graaf WT
Prognostic factors in soft tissue sarcoma patients with lung metastases only receiving first-line chemotherapy. An exploratory, retrospective analysis on fifteen trials of the European Organization for Research and Treatment of Cancer – Soft Tissue and Bone Sarcoma Group (EORTC-STBSG)

Abstract ID: 1835; P024
Poster Session: Breast Cancer – Advanced Disease
Time:  Monday, 28 September 2015, 9:15 – 11:15
Location: Hall C

E. Zikos, I. Ghislain, C. Coens, C. Quinten, V. Balta, K. Tryfonidis, M. Piccart, D. Zardavas, G. Velikova, E. Nagele, V. Bjelic-Radisic, F. Cardoso, M.A.G. Sprangers and A. Bottomley
Health-related quality of life in advanced breast cancer: A systematic review on reporting of methodological and clinical issues in randomized controlled trials

 

Abstract ID: 3023; P275
Poster Session: Lung Cancer – Localised/Local Regional
Time: Sunday, 27 September 2015, 9:15 – 11:15
Location: HALL C

J. Menis, Nicolas Girard, Baktiar Hasan, Benjamin Besse
Pan-European survey on thymic malignancies: A collaboration of the EORTC Lung Cancer Group (LCG) with the RYTHMIC network

 

 

John Bean, PhD
EORTC, Medical Science Writer